Agent | N | Age in years | Median follow-up in months (Range) | TP53/ | CK | ORR | PFS (2y) | OS (2y) | Ref. |
---|---|---|---|---|---|---|---|---|---|
(Study) | (R/R-TN) | (Range) | d17p | (CR) | (median in months) | (median in months) | |||
Ibrutinib | 132 | 68 | 46 | 34 | 41 | 86% | n.r. | n.r. | (O'Brien et al., 2016) |
(NCT01105247/NCT01109069) | (101-31) | (37-84) | (0-67) | (14%) | (not reached) | (not reached) | |||
Ibrutinib + rituximab | 40 | 65 | 47 | 21 | 15/28 | 95% | 62% | 78% | (Jain et al., 2017) |
(36-4) | (35-82) | (36-51) | (23%) | (45mo) | (not reached) | ||||
Ibrutinib | 84 | n.r. | 34 | 53 | n.r. | n.r. | 84% at 3y | n.r. | (Ahn et al., 2017) |
(NCT01500733) | (32-52) | (0.1-50) | Â | (not reach) | |||||
Ibrutinib | 144 | 64 | 28 | 144 | n.r. | 83% | 63% | 75% | (O'Brien et al., 2016) |
(NCT01744691) | (144-0) | (n.r.) | (n.r.) | (n.r.) | (not reached) | (not reached) | |||
Ibrutinib +/- rituximab +/- bendamustine | 88 | 66 | 28 | 34/40 | 21/56 | 94% | n.a. | n.r. | (Thompson et al., 2015) |
(88-0) | (35-83) | (14-48) | (17%) | ||||||
Ibrutinib | 195 | 67 | 19 | 79/154 | 39/153 | 90% | 74% | 86% at 1.5y | (Brown et al., 2018) |
(NCT01578707) | (195-0) | (30-86) | (n.r.-26) | Â | (n.r.) | (n.r.) | |||
Ibrutinib | 621 | 60 | 17 | 26% | 73/216 | n.r. | 64% | 79% | (Mato et al., 2016) |
Connect® CLL Registry | (536-80) | (22-95) | (n.r.) |  | (35mo) | (not reached) | |||
Ibrutinib | 315 | 69 | 16 | 90/263 | n.a. | n.r. | 74% at 1y | 84% at 1y | (Forum, 2016) |
UK CLL Forum | (315-0) | (42-93) | (n.r.) | Â | (n.r.) | (n.r.) | |||
Ibrutinib | 95 | 69 | 10 | 50/80 | n.a. | 84% | 75% at 1y | 82% at 1y | (Winqvist et al., 2016) |
Swedish CUP | (94-1) | (42-86) | (n.r.) | (3%) | (not reached) | (not reached) | |||
Idelalisib | 54 | 63 | n.r. | 13 | n.a. | 72% | n.r. | n.r. | (Brown et al., 2014) |
(NCT00710528) | (54-0) | (37-82) | Â | (16mo) | (not reach) | ||||
Idelalisib + rituximab | 110 | 71 | 13 | 46 | n.a. | 81% | 38% | 72% | (Furman et al., 2014) |
(NCT01539512) | (110-0) | (48-90) | (n.r.) | (0%) | (19mo) | (not reached) | Â | ||
Idelalisib + ofatumumab | 174 | 68 | 16 | 70 | n.a. | 75% | ≈30% | ≈65% | (Jones et al., 2017) |
(NCT01659021) | (174-0) | (61-74) | (n.r.) | (<1%) | (16mo) | (not reached) | |||
Idelalisib + bendamustine | 207 | 62 | 14 | 69 | n.a. | n.r. | 48% | 75% | (Zelenetz et al., 2017) |
(NCT01569295) | (207-0) | (56-69) | (n.r.) | Â | (21mo) | (not reached) | |||
Venetoclax | 116 | 66 | 17 | 31 | n.a. | 79% | 52% | 84% | (Roberts et al., 2016) |
(NCT01328626) | (116-0) | (36-86) | (1-26) | (20%) | (25 mo) | (not reached) | |||
Venetoclax + rituximab | 49 | 68 | 28 | 10/32 | n.a. | 86% | 82% | 94% | (Seymour et al., 2017) |
(NCT01682616) | (49-0) | (50-88) | (1-42) | (51%) | (not reached) | (not reached) | |||
Venetoclax | 107 | 67 | 12 | 107 | n.a. | 79% | 72% at 1y | 87% at 1y | (Stilgenbauer et al., 2016) |
(NCT01889186) | (107-0) | (37-85) | (n.r.) | (16%) | (not reached) | (not reached) |